Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Scleroderma Lung Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

NCT01776398
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Idiopathic Pulmonary Fibrosis (IPF), Rheumatoid Arthritis-Associated Interstitial Lung Disease, Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 5, 2026, 11:10 PM EDT
Terminated No phase listed Observational

Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)

NCT00706082
View directory record Official record
Conditions
Systemic Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2012 · Synced Sep 5, 2026, 11:10 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 5, 2026, 11:10 PM EDT
Active, not recruiting Phase 2 Interventional

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

NCT06843239
View directory record Official record
Conditions
Systemic Sclerosis (SSc), Scleroderma
Interventions
Tibulizumab, Placebo
Biological · Other
Lead sponsor
Zura Bio Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Plantation, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 5, 2026, 11:10 PM EDT
Completed No phase listed Observational

Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension

NCT01729611
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
17 Years to 90 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 5, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)

NCT01933334
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Pirfenidone
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
18
States / cities
Scottsdale, Arizona • Los Angeles, California • Redwood City, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Sep 5, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

NCT05559580
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Avenciguat (BI 685509), Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Covina, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 5, 2026, 11:10 PM EDT
Terminated Phase 1 Interventional

A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)

NCT04948554
View directory record Official record
Conditions
Systemic Sclerosis With and Without Interstitial Lung Disease
Interventions
MK-2225, Placebo
Biological
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Sep 5, 2026, 11:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Novel Screening Strategies for Scleroderma PAH

NCT01959815
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Scleroderma
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
30 Years and older
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 5, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis

NCT03313180
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 5, 2026, 11:10 PM EDT
Completed No phase listed Observational

Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough

NCT01667042
View directory record Official record
Conditions
Scleroderma Lung
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Sep 5, 2026, 11:10 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401
View directory record Official record
Conditions
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Hypersensitivity Pneumonitis, Interstitial Lung Disease With Systemic Sclerosis
Interventions
AP01, Placebo
Drug · Other
Lead sponsor
Avalyn Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
61
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 5, 2026, 11:10 PM EDT
Completed Phase 1 Interventional

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

NCT02426229
View directory record Official record
Conditions
Scleroderma, Interstitial Lung Disease
Interventions
dabigatran etexilate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 5, 2026, 11:10 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hormonal, Metabolic, and Signaling Interactions in PAH

NCT01884051
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 90 Years
Enrollment
1,899 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2032
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 5, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional

Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

NCT04797286
View directory record Official record
Conditions
Scleroderma, Mildly Elevated Pulmonary Pressures
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 5, 2026, 11:10 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Clinical Trial for CTD-ILD Treatment

NCT01424033
View directory record Official record
Conditions
Interstitial Lung Disease, Connective Tissue Disease
Interventions
N-Acetylcysteine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 5, 2026, 11:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 5, 2026, 11:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis

NCT00764309
View directory record Official record
Conditions
Scleroderma
Interventions
dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Scottsdale, Arizona • Los Angeles, California • Farmington, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Sep 5, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional Results available

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease

NCT01559129
View directory record Official record
Conditions
Scleroderma, Systemic, Sclerosis, Systemic, Systemic Scleroderma, Systemic Sclerosis, Interstitial Lung Disease
Interventions
Pomalidomide (CC-4047), Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
20
States / cities
Los Angeles, California • Rancho Mirage, California • Newark, Delaware + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 5, 2026, 11:10 PM EDT
Not listed No phase listed Observational

Pulmonary Care and Research Collaborative Patient Registry

NCT05445817
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
Pulmonary Care and Research Collaborative Limited
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 5, 2026, 11:10 PM EDT
Not listed No phase listed Observational

Lung Clearance Index to Identify Scleroderma Patients at Risk for ILD

NCT04535245
View directory record Official record
Conditions
Scleroderma
Interventions
LCI testing
Diagnostic Test
Lead sponsor
National Jewish Health
Other
Eligibility
21 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Sep 5, 2026, 11:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension

NCT02331225
View directory record Official record
Conditions
Systemic Sclerosis, Pulmonary Hypertension, Scleroderma
Interventions
No intervention given
Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 5, 2026, 11:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microvascular and Fibrosis Imaging Study

NCT01758250
View directory record Official record
Conditions
Autoimmune Diseases, Sickle Cell Disease, Chronic Graft Versus Host Disease
Interventions
Acoustic Radiation Force Impulse (ARFI), Laser Doppler Flowmetry (LDF), Laser Doppler Perfusion Imaging (LDI), Optical Coherence Tomography (OCT), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC)
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Sep 5, 2026, 11:10 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

NCT05878717
View directory record Official record
Conditions
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
Interventions
Belimumab, Placebo
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
24
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 5, 2026, 11:10 PM EDT